摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to immunology. What is presented is a prophylactic or therapeutic agent for IL-31 related itching, containing an effective amount of anti-NR10 antibody, possessing NR10-neutralising (alternative name IL-31RA) activity as an active ingredient, and pharmaceutically acceptable additives, wherein the anti-NR10 antibody represents an antibody, which contains the heavy-chain amino acid sequence SEQ ID NO: 17 and the light-chain amino acid sequence SEQ ID NO: 18, or its humanised antibody. What is presented is using the anti-NR10 antibody containing the heavy- and light-chain amino acid sequences SEQ ID NO: 17 and SEQ ID NO: 18 respectively, or its humanised antibodies for preparing the prophylactic or therapeutic agent for IL-31 related itching. What is described is a method for preventing or treating IL-31 related itching, which involves the stage of administering the anti-NR10 antibody containing the heavy-chain amino acid sequence SEQ ID NO: 17 and the light-chain amino acid sequence SEQ ID NO: 18, or its humanised antibodies.EFFECT: invention enables suppressing IL-31 overexpression itching.3 cl, 5 dwg, 2 ex |